phrykt

AVITA Medical, Inc. (RCEL): who owns it and who trades it

As of Nov 16, 2026, RCEL insiders reported 14 purchases worth $235K in the last 12 months. The largest buyer was Joseph Fralin Woody (Director), with $189K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AVITA Medical

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RCEL

74 funds and institutions reported RCEL shares worth $20.4M at the end of Q2 2026, about 16% of the company. The largest holder is Vanguard Capital Management LLC with 4.3%.

Funds and institutions (13F) 16%Everyone else 84%

10 largest owners, by share of the company

Vanguard Capital Management LLC4.3%
BlackRock, Inc.1.8%
Geode Capital Management, LLC1.1%
Marshall Wace, LLP1.1%
AQR Capital Management LLC1.0%
Morgan Stanley0.7%
Vanguard Fiduciary Trust Co0.6%
NewEdge Advisors, LLC0.5%
Macquarie Group Ltd0.5%
State Street Corp0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC1.33M4.33%$5.5M-0%
BlackRock, Inc.564,9521.84%$2.3M-50%
Geode Capital Management, LLC339,8221.10%$1.4M-37%
Marshall Wace, LLP338,3871.10%$1.4M+544%
AQR Capital Management LLC321,0131.04%$1.3M+240%
Morgan Stanley200,4620.65%$828K+27%
Vanguard Fiduciary Trust Co182,4020.59%$753K-6%
NewEdge Advisors, LLC148,9310.48%$615KNew
Macquarie Group Ltd144,1640.47%$595K+1111%
State Street Corp128,9770.42%$533K-70%
Quantinno Capital Management LP105,2480.34%$435K+368%
Divisadero Street Capital Management, LP100,0000.32%$413KNo change
UBS Group AG84,0330.27%$347K+35%
Goldman Sachs Group Inc76,7370.25%$317K-23%
Northern Trust Corp68,9730.22%$285K-62%
Qube Research & Technologies Ltd63,7840.21%$263KNew
Arrowstreet Capital, Limited Partnership60,7460.20%$251KNew
XTX Topco Ltd57,1610.19%$236KNew
BNP Paribas Financial Markets53,9580.18%$223K+1604%
Bank of America Corp51,6670.17%$213K-17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RCEL insiders reported $235K of open-market purchases and $0 of sales.

Purchases, 12 months
$235K
14 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 12, 2026
Filed Aug 24, 2026

Purchases and sales by month

$197K$197KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 12, 2026David D O'TooleCFOPurchase2,000$3.97$7.9KForm 4
Jun 9, 2026Joseph Fralin WoodyDirectorPurchase5,200$4.00$20.8KForm 4
Jun 9, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.18$20.9KForm 4
Jun 9, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.20$21KForm 4
Jun 3, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.09$20.4KForm 4
Jun 3, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.10$20.5KForm 4
Jun 2, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.21$21.1KForm 4
Jun 2, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.18$20.9KForm 4
Jun 1, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.26$21.3KForm 4
Jun 1, 2026Joseph Fralin WoodyDirectorPurchase5,000$4.34$21.7KForm 4
May 20, 2026David D O'TooleCFOPurchase2,000$4.26$8.5KForm 4
May 19, 2026David D O'TooleCFOPurchase2,000$4.24$8.5KForm 4
Mar 11, 2026David D O'TooleCFOPurchase1,800$4.78$8.6KForm 4
Feb 19, 2026David D O'TooleCFOPurchase3,000$4.15$12.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joseph Fralin WoodyDirector$189K–Jun 9, 2026
David D O'TooleCFO$46K–Jun 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RCEL short interest

Moderate short interest. 9.1% of RCEL shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.81M RCEL shares were sold short, 9.1% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 458,652 shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

9.08%May 15Oct 3012.0%

Days to cover

6.1May 15Oct 3017.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.81M9.08%-1%458,6526.1
Oct 15, 20262.84M9.17%-2%371,6567.6
Sep 30, 20262.89M9.34%+0%313,8789.2
Sep 15, 20262.89M9.33%-2%273,71910.5
Aug 31, 20262.94M9.50%+7%424,1046.9
Aug 14, 20262.75M8.89%+5%1.10M2.5
Jul 31, 20262.61M8.47%-0%234,96611.1
Jul 15, 20262.62M8.50%+3%337,7787.8
Jun 30, 20262.53M8.22%-22%421,8356.0
Jun 15, 20263.22M10.47%-2%239,37013.5
May 29, 20263.30M10.72%-7%215,06115.3
May 15, 20263.55M11.53%+4%318,20111.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

AVITA Medical company events

AVITA Medical filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Nov 2, 2026AnnouncementShared information with investors. Filing
  3. Aug 11, 2026AgreementThe Company and Stedical Scientific, Inc. entered into a Global Amendment of their existing distribution agreement and manufacturing agreement. Filing
  4. Aug 6, 2026VoteAmended an earlier report. Reported shareholder vote results. Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jun 8, 2026AgreementAs disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2026, AVITA Medical, Inc. previously entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP as a lender and the administrative agent. Filing
  7. Jun 4, 2026LeadershipAVITA Medical, Inc. held its 2026 Annual Meeting of Stockholders solely by means of remote communication via live webcast on June 3, 2026 (being June 4, 2026 in Australia). Filing
  8. May 14, 2026ResultsReleased financial results. Filing
  9. May 1, 2026LeadershipAppointments of President and Chief Executive Officer and Chair of the Board of Directors. Filing
  10. Feb 12, 2026ResultsReleased financial results. Filing
  11. Jan 13, 2026AgreementAVITA Medical, Inc. entered into a Credit Agreement and Guaranty and a Security Agreement, by and among the Company, as borrower, Avita Medical Americas, LLC, a wholly-owned subsidiary of the Company, as guarantor and Perceptive Credit Holdings V, LP as a lender and the administrative agent (the… Filing
  12. Jan 5, 2026LeadershipThe Board of Directors of AVITA Medical, Inc. appointed Joe Woody to the Board to serve until the Company’s 2026 Annual Meeting of Stockholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

AVITA Medical financials

Famous investors that hold RCEL

3 of the 50 well-known investors we track reported holding RCEL in their latest 13F filing. The largest position is Israel Englander's, worth $4.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026370,643$4.3M0.0%+2302%
Ken Griffin · Citadel AdvisorsQ3 2026227,677$2.7M0.0%+972%
Jim Simons · Renaissance TechnologiesQ3 202619,100$224K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about AVITA Medical, Inc. (RCEL) stock

Who owns the most RCEL stock?

The largest reported owner of AVITA Medical, Inc. (RCEL) is Vanguard Capital Management LLC, with 4.3% of the company. In total, 74 funds and institutions reported holding RCEL at the end of Q2 2026, together about 16% of the shares. See the largest owners.

Are RCEL insiders buying or selling?

In the last 12 months, RCEL insiders reported 14 open-market purchases worth $235K and no sales. The latest trade was on Jun 12, 2026. See every trade.

What is the short interest in RCEL?

As of Oct 30, 2026, 2.81M RCEL shares were sold short, 9.1% of the shares outstanding, down 1.0% from the report before. At the average daily volume of 458,652 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Which famous investors hold RCEL?

3 of the 50 well-known investors we track reported RCEL in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $4.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.